You are Invited to Join LSN in Atlanta, Georgia, for RESI South, and Barcelona, Spain, for RESI Europe  

18 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) is excited to announce two significant RESI partnering events in 2024. The first, RESI South, will be held in Atlanta, Georgia, on March 25, and the second, RESI Europe, will occur in Barcelona, Spain, on June 17th. These events mark a strategic expansion of LSN’s global partnering platform, providing a unique opportunity for its network of capital investors and licensing partners to engage with two dynamic innovation regions. The Super Early Bird rates are currently available for two upcoming RESIs. This is an excellent opportunity to register at a reduced cost before the deadline.

RESI South in Atlanta is particularly significant as it will showcase the burgeoning life science innovation ecosystem in the Southeastern United States. The Southeast LifeSci Investor Coalition, representing seven southern states (AL, FL, GA, NC, SC, TN, and VA), has united to spotlight the region’s wealth of early-stage drugs, devices, diagnostics, and digital health technologies. Thousands of startups are invigorating this innovation region. LSN estimates that hundreds of startups with technology transfer licenses are ready to explore the partnering opportunities that RESI South will bring.

The untapped potential of the Southeast is underscored by its receipt of 5.5 billion in NIH funding and 8.3 billion in academic research expenditures, making up 16% of all academic Bioscience R&D U.S. funding. LSN is thrilled to partner with the Southeast LifeSci Investor Coalition and is confident that its global partnering network will be able to explore this previously underserved market.

Following RESI South, LSN will host RESI Europe in Barcelona, Spain. The BioRegion of Catalonia has emerged as a leading force in the global life science landscape, boasting a thriving biotech and medtech startup ecosystem. The region’s strategic focus on business automation, connectivity, and the application of AI within diagnostics and treatments has attracted international life science players and positioned Catalonia as a hub for advanced therapeutics.

RESI Europe in Barcelona will leverage the BioRegion and showcase the broader Spanish life science ecosystems. RESI Europe also provides a great opportunity for global startups in Europe, North America, and APAC to get to Europe and meet the early-stage global players in the LSN European network. LSN expects a strong showing from its global capital investor and licensing partner network to attend this inaugural event.

LSN’s RESI Partnering Events in 2024 are set to provide a unique platform for global investors and startups to engage with two vibrant innovation regions. These events underscore LSN’s commitment to fostering cross-border partnerships and driving innovation across the global life science landscape. For more information about LSN and its initiatives, you can visit their official website at Life Science Nation.

Register-now-button-new

RESI-South-2024-11oo
RESI-SPAIN-1100

RESI JPM Recap: Record Investor Registrations and 3000 Connections Made 

18 Jan

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

Life Science Nation’s (LSN) biggest Redefining Early Stage Investments (RESI) event of the year, taking place during JP Morgan Healthcare week in San Francisco, was a huge success last week. With over 3000 meetings and connections made through RESI, it will be weeks before the true outcomes will be fully realized. With over 1100 attendees, spanning 35 countries and 5 continents, RESI hit a record high investor registrations, with 650 investors registered to attend, both in person and virtually. Of these investors, one third were investors who were new to RESI. RESI is the premier event for investors wanting to connect with early stage life science startups, and for every event, the LSN Investor Research team received outreach from new investors interested in joining our network and connecting with exciting new innovators.

In addition to meetings, RESI’s compelling content provides startups with opportunities to learn from investors, industry experts and their peers tips and techniques to make their fundraise successful. With panels such as the Family Offices, Big Pharma, Health System Partners and Cross Border Investors, companies were able to learn how different investor types partner in the early stages, and how to approach these investors most successfully. Other panels covered different sectors, such as Early Stage Therapeutics and Medical Devices, and even focused on areas gaining increasing traction such as Mental and Behavioral Health. These investor panels focused on current trends in the industry, and where they think it is headed in the near future. Panels hosted by industry experts focused on challenges companies can face and experts that can help them avoid issues that can delay them in their quest to bring their technologies to market. Cambridge Scientific hosted a session on procuring space in incubators and labs, as well as equipment, and how to navigate that to best advantage. Husch Blackwell hosted a session on navigating a fundraise with a complex technology, and how to explain your technology to best advantage when there is a complicated regulatory and intellectual property landscape.

The LSN network continues to expand with every RESI we organize, with new attendees and new content, and we are excited for 2024, which will include several new locations hosting our RESI conference. Check out our schedule for 2024, and join us for what is sure to be a full year of fantastic events.

RESI-South-2024-11oo

Hot Investor Mandate: USA-Based VC Invests in Global Companies Addressing Mental & Behavioral Health

18 Jan

A venture capital fund founded in 2020 and headquartered in California invests in life science and healthcare companies that focus on mental health and wellness. The firm prefers to invest in Seed rounds but is open to Pre-Seed as well, with typical check sizes ranging from $500k-700k USD. The firm is open to global companies. 

The firm is open to drugs, digital health, diagnostics, and device companies with indications in psychiatry, neurology, and neuropsychiatry. Some categories of interest include psychedelic medicine & new compounds, neurotech & human augmentation, precision psychiatry, digital therapeutics, holistic medicine, metabolic psychiatry, digital health, and AI. The firm can invest as early as pre-clinical and in-development stages. 

The firm can co-lead for Pre-Seed rounds and does not require to take a board seat. The firm prefers to have at least one co-founder be full-time. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: Corporate Venture Arm of Global CRDMO Seeks Biotech Investment Opportunities in US, China, and Europe 

18 Jan

A corporate venture arm of a leading global Contract Research, Development and Manufacturing Organization (CRDMO) founded in 2018 is open to investing in anywhere from seed to IPO financing rounds. Initial investment size can vary and follow-on investment is possible. The firm primarily seeks opportunities in the US, and is open to China and Europe as well. The venture arm does not lead rounds and prefers companies with a lead investor in place. Depending on the investment size and deal terms, the fund may consider an observer seat or board seat. The venture arm makes equity investments only and does not have an equity-for-service model. 
 
Separately from the corporate venture arm, the organizations runs a program that collaborates with over 25 partners, such as accelerators, seed/venture capital firms, incubators, and other similar programs to provide startups various tools and resources to accelerate biologics and vaccine development, including credits for the organization’s technology platforms. Startups must be an active participant or referred by a Program Partner to be eligible. 

The venture arm will consider a wide range of biotech assets, from antibody drug, protein therapeutics, vaccines, DNA and mRNA drugs. The fund is also open to orphan drugs. One type of asset that the fund does not consider cell and gene therapy. 

The venture arm does not lead rounds therefore would only invest when a lead investor is secured. The fund is open to working with new or first time founders but hopes to see that the team has a good supportive network. The fund is interested in working with founders who are open to advice and suggestions. 

The venture’s team is open to meeting with companies in their initial stage of fundraising and will track their progress. But they will only look deeper into the opportunities when a lead investor is in play and the company is close to signing a term sheet.  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: Venture Fund Invests in 510K and PMA Medical Devices Addressing Cardiology, Neurology, and Surgery 

18 Jan

A venture fund founded in 2019 with headquarters in the Bay Area, an $100M AUM, and a current fund size of $50M USD, is dedicated towards medical device-centered technologies from Series A to C. The firm is open to earlier-stage opportunities if the project aligns with the firm’s interests. The typical initial check size is $1-5M, and the firm plans to make 4-5 investments in the next year. The firm invests globally with a focus in the United States. 

The firm invests in PMA and 510K medical devices, specifically those pertaining to surgical innovation, in development and clinical phases. The firm does not invest in heath information systems or wearables. Otherwise, the firm considers device-approached technologies in the therapeutics, diagnostics, and digital health space in development and clinical phases. While the firm is open to all indications, cardiology, neurology, and surgery are areas of interest. 

The firm does not have any requirements of the management team. The firm will both lead and co-lead depending on the area of expertise. Board seating will be required when leading investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: Venture Arm of Innovation Hub Leads Pre-Seed and Seed Rounds for Life Science and Healthcare Startups in the US 

18 Jan

A venture arm of an innovation hub headquartered in California for life science, medtech, and technology companies invests in Pre-Seed and Seed stage biotech, device, and ag-tech companies in the U.S. The firm acts as a lead investor. For Pre-Seed rounds, typical check size falls between $250k-1M and for Seed rounds, typical check size falls between $1M-3M. For their main fund, it is not required for companies to go through the accelerator program, however the resources are available and encouraged 

In terms of life sciences and healthcare, the firm is interested in biotech and medical devices. For biotech, the firm is subsector agnostic, including drug development and bio tools, for device, the firm is open to all classes. The firm is also indication-agnostic. The firm typically looks at companies in pre-clinical stages. 

The firm requires companies to already be incorporated and have their CEOs to be fulltime. The firm may take a board seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

RESI JPM 2024 Program Guide

4 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) releases the Program Guide for LSN’s RESI flagship event, RESI JPM, taking place next week, January 9 in person and on January 10-11 virtual! This hybrid conference will take place at the Marines’ Memorial Club & Hotel in San Francisco, and we are excited to release the digital version of the RESI Program Guide. Check out the various panelists, exhibitors, and workshops participating in this RESI. In addition, make sure to check out the Innovator’s Pitch Challenge, where over 50 companies will pitch to a panel of investor judges. Registration is still open for both in-person and virtual attendance. 

RESI-JPM-PG-Cover

Register-now-button-new

RESI-SF-2024-Banner-1100px new

← Older Entries
Newer Entries →